179 related articles for article (PubMed ID: 38589827)
1. Assessing antiviral treatment efficacy and risk factors for severe COVID-19 in kidney transplant recipients during the Omicron subvariant-dominant period: a retrospective study.
Sakaguchi T; Mitsuke A; Osako Y; Yamada Y; Takeyama H; Ogawa R; Takahashi K; Hirohata Y; Yamamoto S; Arima J; Fukumoto W; Sugita S; Inoguchi S; Matsushita R; Yoshino H; Tatarano S; Enokida H
BMC Nephrol; 2024 Apr; 25(1):124. PubMed ID: 38589827
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: A retrospective cohort study.
Chen Y; Lin Y; Lu H; Wu X; Pan Y; Xia A; Pang L; Ye W; Xu F
Diagn Microbiol Infect Dis; 2024 Aug; 109(4):116353. PubMed ID: 38776665
[TBL] [Abstract][Full Text] [Related]
3. Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge.
Radcliffe C; Palacios CF; Azar MM; Cohen E; Malinis M
Am J Transplant; 2022 Oct; 22(10):2458-2463. PubMed ID: 35583664
[TBL] [Abstract][Full Text] [Related]
4. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and outcomes of hospitalized kidney transplant recipients with COVID-19 infection in China during the Omicron wave: a single-center cohort study.
Lv D; Xie X; Yang Q; Chen Z; Liu G; Peng W; Wang R; Huang H; Chen J; Wu J
J Zhejiang Univ Sci B; 2024 Jun; 25(6):529-540. PubMed ID: 38910497
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
[TBL] [Abstract][Full Text] [Related]
7. Preliminary Clinical Experience of Molnupiravir to Prevent Progression of COVID-19 in Kidney Transplant Recipients.
Villamarín M; Márquez-Algaba E; Esperalba J; Perelló M; Los Arcos I; Campany D; Moreso F; Len O
Transplantation; 2022 Nov; 106(11):2200-2204. PubMed ID: 35915545
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of physicians prescribing of COVID-19 guideline-directed outpatient treatments in a primary care walk-in clinic.
Denning K; Sheppard J; Carico R
J Am Pharm Assoc (2003); 2024; 64(2):530-534. PubMed ID: 38151202
[TBL] [Abstract][Full Text] [Related]
9. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
Jayk Bernal A; Gomes da Silva MM; Musungaie DB; Kovalchuk E; Gonzalez A; Delos Reyes V; Martín-Quirós A; Caraco Y; Williams-Diaz A; Brown ML; Du J; Pedley A; Assaid C; Strizki J; Grobler JA; Shamsuddin HH; Tipping R; Wan H; Paschke A; Butterton JR; Johnson MG; De Anda C;
N Engl J Med; 2022 Feb; 386(6):509-520. PubMed ID: 34914868
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 after kidney transplantation: Early outcomes and renal function following antiviral treatment.
Elec AD; Oltean M; Goldis P; Cismaru C; Lupse M; Muntean A; Elec FI
Int J Infect Dis; 2021 Mar; 104():426-432. PubMed ID: 33453396
[TBL] [Abstract][Full Text] [Related]
11. Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study.
Kneidinger N; Hecker M; Bessa V; Hettich I; Wald A; Wege S; Nolde AB; Oldigs M; Syunyaeva Z; Wilkens H; Gottlieb J
Infection; 2023 Jun; 51(3):749-757. PubMed ID: 36083405
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents.
Gentry CA; Nguyen PN; Thind SK; Kurdgelashvili G; Williams RJ
Clin Infect Dis; 2024 Feb; 78(2):330-337. PubMed ID: 37619991
[TBL] [Abstract][Full Text] [Related]
13. Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.
Chen MP; Jiang DX; Rang JX; Zhuo HB; Zhou ZG
Sci Rep; 2024 Feb; 14(1):3318. PubMed ID: 38337014
[TBL] [Abstract][Full Text] [Related]
14. Risk factors and multi-pathogen infections in kidney transplant recipients with omicron variant pneumonia: a retrospective analysis.
Chen J; Su Y; Lu M
BMC Infect Dis; 2024 Jun; 24(1):559. PubMed ID: 38834974
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 early curative treatments in kidney transplant recipients: is it really reasonable at the Omicron era?
Tamzali Y; Lundy A; Bleibtreu A; Cazenave M; Mohammadou I; Arzouk N; Galichon P; Marot S; Junot H; Barrou B; Pourcher V; Tourret J
Nephrol Ther; 2023 Nov; 19(6):491-496. PubMed ID: 37915200
[TBL] [Abstract][Full Text] [Related]
16. Clinical Profile and Outcome of COVID-19 in 250 Kidney Transplant Recipients: A Multicenter Cohort Study From India.
Kute VB; Bhalla AK; Guleria S; Ray DS; Bahadur MM; Shingare A; Hegde U; Gang S; Raju S; Patel HV; Jain S; Godara S; Modi P; Gumber M; Engineer DP; Dalal S; Darji P; Balwani M; Patel AH; Mishra VV
Transplantation; 2021 Apr; 105(4):851-860. PubMed ID: 33350674
[TBL] [Abstract][Full Text] [Related]
17. Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China.
Zhu L; Gong N; Liu B; Lu X; Chen D; Chen S; Shu H; Ma K; Xu X; Guo Z; Lu E; Chen D; Ge Q; Cai J; Jiang J; Wei L; Zhang W; Chen G; Chen Z
Eur Urol; 2020 Jun; 77(6):748-754. PubMed ID: 32317180
[TBL] [Abstract][Full Text] [Related]
18. Effect of pre-hospitalization use of oral antiviral agents on reducing critical illness and mortality for patients with COVID-19 pneumonia.
Yii YC; Shih HM; Chen CL; Lai ZL; Hsu YL; Lai CH; Hsueh PR; Cho DY
Int J Antimicrob Agents; 2024 Jan; 63(1):107020. PubMed ID: 37898365
[TBL] [Abstract][Full Text] [Related]
19. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients.
Piñana JL; Heras I; Aiello TF; García-Cadenas I; Vazquez L; Lopez-Jimenez J; Chorão P; Aroca C; García-Vidal C; Arroyo I; Soler-Espejo E; López-Corral L; Avendaño-Pita A; Arrufat A; Garcia-Gutierrez V; Arellano E; Hernández-Medina L; González-Santillana C; Morell J; Hernández-Rivas JÁ; Rodriguez-Galvez P; Mico-Cerdá M; Guerreiro M; Campos D; Navarro D; Cedillo Á; Martino R; Solano C;
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896843
[TBL] [Abstract][Full Text] [Related]
20. Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant Recipients.
Poznański P; Augustyniak-Bartosik H; Magiera-Żak A; Skalec K; Jakuszko K; Mazanowska O; Janczak D; Krajewska M; Kamińska D
Viruses; 2022 Oct; 14(10):. PubMed ID: 36298779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
